Using the industry peer median P/E multiple (trailing + forward), IDEXX Laboratories, Inc. (IDXX) has a fair value of $310.31 based on 7 comparable companies in the Medical - Diagnostics & Research industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing P/E | Forward P/E | |
|---|---|---|---|
| IDEXX Laboratories, Inc.IDXX | 46,601 | 44.2x | 39.7x |
| Cencora, Inc.COR | 61,941 | 40.0x | 18.1x |
| Becton, Dickinson and CompanyBDX | 57,532 | 27.2x | 12.7x |
| Zoetis Inc.ZTS | 51,848 | 19.5x | 16.8x |
| Cardinal Health, Inc.CAH | 49,047 | 32.3x | 20.2x |
| Edwards Lifesciences CorporationEW | 47,986 | 45.1x | 27.8x |
| Agilent Technologies, Inc.A | 32,180 | 24.9x | 19.1x |
| IQVIA Holdings Inc.IQV | 28,849 | 21.7x | 13.4x |
| Industry Median | 27.2x | 18.1x | |
| (*) Profit after tax | 1,059 | 1,174 | |
| Equity Value | 28,858 | 21,211 | |
| (/) Outstanding shares | 81 | 81 | |
| Fair Price | $358 | $263 | |
This P/E relative valuation uses the industry peer median Price-to-Earnings ratio to estimate fair value. Both trailing (last 12 months) and forward (next fiscal year analyst estimates) P/E multiples are computed independently.
The industry median trailing P/E is applied to the company's TTM net income, and the forward P/E to analyst-estimated net income. Each produces an equity value divided by shares outstanding to yield a fair price per share. The selected fair value is the average of the trailing and forward legs.